Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: Rare complication or incidental finding?

Dermatology

Volumn 224, Issue 2, 2012, Pages 106-109

  Cavalli, R ^a   Buffon, R B ^a   De Souza, M ^a   Colli, A M ^a   Gelmetti, C ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hemangioma; Hyperkalemia; Infancy; Propranolol; Tumor lysis syndrome

Indexed keywords

PROPRANOLOL;

ARTICLE; CAPILLARY HEMANGIOMA; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPERPHOSPHATEMIA; INCIDENTAL FINDING; INFANT; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VASCULAR TUMOR;

ANTINEOPLASTIC AGENTS; FEMALE; HEMANGIOMA, CAPILLARY; HUMANS; HYPERKALEMIA; HYPERPHOSPHATEMIA; INFANT; NEOPLASTIC SYNDROMES, HEREDITARY; PROPRANOLOL; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SKIN ULCER; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 84861895860     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000337553     Document Type: Article

References (23)

1. Léauté-Labréze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 17: 2649-2651. (Pubitemid 351831393)
2. Hogeling M, Adams S, Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128:e259-266.
3. Zimmermann AP, Wiegand S, Werner JA, Eivazi B: Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinol 2010; 74: 338-342.
4. Storch CH, Hoeger PH: Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274.
5. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767-2778.
6. Murad MH, Coto-Yglesias F, Wang AT, et al: Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94: 741-745.
7. Holland KE, Frieden IJ, Frommelt PC, et al: Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146: 775-778.
8. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M: Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010; 126:e1589-e1593.
9. Rosa RM, Silva P, Young JB, et al: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302: 431-434. (Pubitemid 10169247)
10. Brown RS: Extrarenal potassium homeostasis. Kidney Int 1986; 30: 116-127. (Pubitemid 16059580)
11. Hayward LJ, Kim JS, Ming-Yang L, et al: Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness. J Clin Invest 2008; 118: 1437-1449. (Pubitemid 351500437)
12. Tannock I: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978; 62: 1117-1133. (Pubitemid 9015322)
13. Jona JZ: Progressive tumor necrosis and lethal hyperkalemia in a neonate with sacrococcygeal teratoma (SCT). J Perinatol 1999; 19: 538-540.
14. Chang LC, Haggstrom AN, Drolet BA, et al: Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-367.
15. Thomas RF, Hornung RL, Manning SC, et al: Hemangiomas of infancy: treatment of ulceration in the head and neck. Arch Facial Plast Surg 2005; 7: 312-315. (Pubitemid 43973814)
16. Saint-Jean M, Léauté-Labréze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, et al: Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64: 827-832.
17. Kim LHC, Hogeling M, Wargon O, Jiwane A, Adams S: Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46: 759-763.
18. Pandey A, Gangopadhyay AN, Sharma SP, et al: Conservative management of ulcerated haemangioma -twenty years' experience. Int Wound J 2009; 6: 59-62.
19. Metz BJ, Rubenstein MC, Levy ML, et al: Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004; 140: 867-870. (Pubitemid 38917857)
20. Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11. (Pubitemid 39331101)
21. Davidson MB, Thakkar S, Hix JK, et al: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546-554. (Pubitemid 38452647)
22. Bishop MR, Cairo MS, Coccia PF: Tumor lysis syndrome; in Abeloff MD (ed): Clinical Oncology, ed 3. Philadelphia, Elsevier/Churchill Livingstone, 2004, pp 987-992.
23. Rheingold S, Lange B: Oncologic emergencies; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 1202-1230.